COVID vaccine INO-4800 is just one piece of the Inovio (INO) puzzle.
Addressing the Human Papilloma Virus remains a high priority for Inovio.
Results from the PHI and PHII VGX3100 trials are promising in the fight against HPV types 16 and 18.
INO-3107 is granted "Orphan Drug Designation" by the US Food and Drug Administration. Is there more to follow?
Inovio will still be moving forward with their efforts to manufacture 1,000,000 doses of the COVID-19 INO-4800 vaccine before the end of 2020 through manufacturers suited to handle the volume, like Richter-Helm BioLogics.
David M. Eberhart 8/2/2020